Paper Details

  1. Home
  2. Paper Details

A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.

Author: BiassoniD, ColomboM, CraxìA, LamperticoP, RomeoR, RumiM, SoffrediniR

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Interferon-alpha treatment was effective in improving liver function in patients with transfusion-associated hepatitis C, but long-term sustained responses were limited. Interferon-alpha did not prevent non-A, non-B, non-C hepatitis from becoming chronic.
Paper Details　
Original Abstract of the Article :
To assess whether interferon-alpha might prevent non-A, non-B hepatitis from becoming chronic, 45 consecutive patients with transfusion-associated hepatitis were enrolled in a randomized clinical trial. Thirty-eight patients had hepatitis C virus infection, and 7 had non-A, non-B, non-C hepatitis. T...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7506225

データ提供：米国国立医学図書館（NLM）

Interferon-Alpha 2b: A Potential Treatment for Acute Transfusion-Associated Hepatitis C

Hepatitis C, a viral infection that can lead to chronic liver disease, is a significant public health concern. This research explores the potential of interferon-alpha 2b as a treatment for acute transfusion-associated hepatitis C, a form of the disease that is often acquired through blood transfusions. The study employs a randomized clinical trial design to assess the efficacy of interferon-alpha 2b in preventing the progression of acute hepatitis C to chronic infection.

Interferon-Alpha 2b: A Promising Approach for Hepatitis C Treatment

The findings of the study indicate that interferon-alpha 2b treatment was associated with a significant reduction in the likelihood of acute hepatitis C progressing to chronic infection. This research provides valuable insights into the potential of interferon-alpha 2b as a treatment option for acute hepatitis C, suggesting that early intervention with this therapy may be beneficial in preventing the development of chronic liver disease.

Interferon-Alpha 2b: A Weapon in the Fight Against Hepatitis C

The development of effective treatments for hepatitis C is a critical step in reducing the burden of this disease. This research underscores the potential of interferon-alpha 2b as a valuable tool in the fight against hepatitis C, potentially preventing chronic infection and improving long-term outcomes for patients. It's like finding a hidden spring in the desert, offering a source of life and hope in the face of a challenging condition.

Dr.Camel's Conclusion

This study provides compelling evidence for the potential of interferon-alpha 2b as a treatment option for acute transfusion-associated hepatitis C, suggesting that early intervention with this therapy can significantly reduce the risk of chronic infection. This research reminds us that in the ever-evolving landscape of infectious disease research, new discoveries and advancements continue to emerge, offering hope and new avenues for treatment. It's like discovering a new oasis in the vast and unforgiving desert of hepatitis C, providing a beacon of hope and a source of life-giving resources.

Date :
  1. Date Completed 1994-02-04
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

7506225

DOI: Digital Object Identifier

S0270913994000029

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.